Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis

Immunology Letters

Volumn 166, Issue 2, 2015, Pages 103-108

  Zhang, Qing Gang ^a   Qian, Jing ^a   Zhu, Yu Chang ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Bromodomain containing protein 4 (BRD4); Collagen induced arthritis; Fibroblast like synoviocytes; Gene silencing; JQ1; Rheumatoid arthritis

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; AUTOANTIBODY; BROMODOMAIN CONTAINING PROTEIN 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AUTACOID; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; COMPLEMENT COMPONENT C2; CYTOKINE; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; ARTICLE; CELL INVASION; CELL MIGRATION; COLLAGEN-INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AZEPINES; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COMPLEMENT C2; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE TARGETING; HUMANS; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NF-KAPPA B; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; TRIAZOLES;

EID: 84934899453     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.05.016     Document Type: Article

References (33)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
2. Leech M.T., Morand E.F. Fibroblasts and synovial immunity. Curr. Opin. Pharmacol. 2013, 13:565-569.
3. Jung S.M., Kim K.W., Yang C.W., Park S.H., Ju J.H. Cytokine-mediated bone destruction in rheumatoid arthritis. J. Immunol. Res. 2014, 2014:263625.
4. Solomon D.H., Bitton A., Katz J.N., Radner H., Brown E.M., Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis. Arthritis Rheumatol. 2014, 66:775-782.
5. Osta B., Benedetti G., Miossec P.Classical Paradoxical effects of TNF-α on bone homeostasis. Front. Immunol. 2014, 5:48.
6. Siebert S., Tsoukas A., Robertson J., McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev. 2015, 67:280-309.
7. Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 2012, 12:465-477.
8. Wu S.Y., Chiang C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 2007, 282:13141-13145.
9. Xu Y., Vakoc C.R. Brd4 is on the move during inflammation. Trends Cell Biol. 2014, 24:615-616.
10. Meng S., Zhang L., Tang Y., Tu Q., Zheng L., Yu L., et al. BET inhibitor JQ1 blocks inflammation and bone destruction. J. Dent Res. 2014, 93:657-662.
11. Ekwall A.K., Whitaker J.W., Hammaker D., Bugbee W., Wang W., Firestein G.S. The rheumatoid arthritis risk gene, LBH. Regulates growth in fibroblast-like synoviocytes. Arthritis Rheumatol. 2015 Feb 23, 10.1002/art.39060.
12. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
13. Toyoda Y., Tabata S., Kishi J., Kuramoto T., Mitsuhashi A., Saijo A., et al. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 2014, 66:560-568.
14. Raychaudhuri S.P., Raychaudhuri S.K. The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand. J. Rheumatol. 2009, 38:207-215.
15. Mix K.S., McMahon K., McMorrow J.P., Walkenhorst D.E., Smyth A.M., Petrella B.L., et al. Orphan nuclear receptor NR4A2 induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription. Arthritis Rheum. 2012, 64:2126-2136.
16. Trabucco S.E., Gerstein R.M., Evens A.M., Bradner J.E., Shultz L.D., Greiner D.L., et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. 2015, 21:113-122.
17. Wu X., Qi J., Bradner J.E., Xiao G., Bromodomain Chen L.F., extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor (B (NF(B) signaling. J. Biol. Chem. 2013, 288:36094-36105.
18. Tarrant T.K., Liu P., Rampersad R.R., Esserman D., Rothlein L.R., Timoshchenko R.G., et al. Decreased Th17 and antigen-specific humoral responses in CX3 CR1-deficient mice in the collagen-induced arthritis model. Arthritis Rheum. 2012, 64:1379-1387.
19. Denis G.V. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov. Med. 2010, 10:489-499.
20. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
21. Belkina A.C., Nikolajczyk B.S., Denis G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 2013, 190:3670-3678.
22. Burska A., Boissinot M., Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014, 2014:545493.
23. Alghasham A., Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity 2014, 47:77-94.
24. Tak P.P., Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000, 43:2619-2633.
25. Dayer J.M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003, 42(Suppl. 2):ii3-ii10.
26. Dinarello C.A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 2013, 25:469-484.
27. Ma X., Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed. Rep. 2013, 177-184.
28. Zhang Y., Ren G., Guo M., Ye X., Zhao J., Xu L., et al. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. Int. Immunopharmacol. 2013, 15:199-205.
29. Yang J., Sundrud M.S., Skepner J., Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol. Sci. 2014, 35:493-500.
30. Park M.J., Park H.S., Oh H.J., Lim J.Y., Yoon B.Y., Kim H.Y., et al. IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA/1J mice. Exp. Mol. Med. 2012, 44:694-705.
31. Benedetti G. Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur. J. Immunol. 2014, 44:339-347.
32. Tanaka S., Toki T., Yokoyama M., Shimizu H., Yamasaki T., Yoneda Y., et al. A novel inhibitor of I-kappaB kinase beta ameliorates experimental arthritis through downregulation of proinflammatory cytokines in arthritic joints. Biol. Pharm. Bull. 2014, 37:87-95.
33. I.A. Schepetkin, L.N. Kirpotina, D. Hammaker, I. Kochetkova, A.I. Khlebnikov, S.A. Lyakhov, et al., Anti-inflammatory effects and joint protection in collagen-induced arthritis following treatment with IQ-1S, a selective c-Jun N-terminal kinase inhibitor, J. Pharmacol. Exp. Ther. (March) (2015), pii: jpet.114. 220251.